CBA advised Deafarma on its acquisition by Azelis
12-20-2018
Azelis, a Belgian company active in the distribution of chemicals, has acquired the whole capital of Deafarma, which distributes active principles and pharmaceuticals, and whose current quotaholders have been assisted by CBA’s team headed by partner Giuseppe A. Galeano.
| Attachments | ||
|---|---|---|
| CBA advises Deafarma | 682.16 KB |  |